ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Engineering Host-Guest Interactions for Next-Generation Heparin Biosensors.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Heparin, a polyanionic anticoagulant, is widely used clinically but requires neutralization to restore normal blood coagulation. Protamine sulfate (PS) is the standard antidote, yet limitations exist. Herein, a polycationic, cavity-containing pillar[6]arene macrocycle (P12+) demonstrates superior heparin neutralization in physiological media compared to its lower-valency analog P10+, and performance comparable to PS. MTT assays reveal low toxicity of the P12+, suggesting feasibility for in vivo use. Dynamic light scattering reveals that P12+ forms nanoscale complexes below 400 nm, smaller than PS-heparin aggregates. Remarkably, P12+ exhibits enhanced neutralization of low-molecular-weight heparin, a known limitation of PS. Additionally, heparin detection is achieved via a host-guest indicator displacement assay (IDA) using methyl orange (MO). UV-vis studies show ∼80% MO release with P12+, compared to ∼40% with P10+ in the presence of heparin. This response is detectable in undiluted human plasma for P12+, whereas P10+ shows a suitable response in 5% diluted plasma. A fluorescence-based IDA enables sensitive detection down to 0.11 U/mL, below the therapeutic range (0.80-2.00 U/mL). Molecular dynamics simulations support these findings, revealing that weaker host-guest interactions and favorable electrostatics in P12+ facilitate efficient MO release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.